#JCRPharmaceuticals

Effective April 1, 2026, changes will be made to the representative directors, multiple new organizations including the President’s Office and Advanced Biopharmaceutical Research Institute will be established or restructured, and personnel changes for executives and executive officers will be implemented.

For Q3 of the fiscal year ending March 2026, net sales were ¥30,353 million (up 17.3% YoY), operating income was ¥427 million, and net income attributable to owners of parent for the quarter was ¥1,744 million.

The sales forecast for the fiscal year ending March 2026 has been revised upward to ¥39.5 billion (4.5% increase from previous forecast), while operating income was revised downward to ¥400 million (84.6% decrease), and net income attributable to owners of parent was revised downward to ¥1.6 billion (46.7% decrease).

For the third quarter of FY March 2026, net sales were 30,353 million yen, a 17.3% increase year-over-year. Operating income turned positive to 427 million yen. Full-year earnings guidance was revised to net sales of 39,500 million yen and operating income of 400 million yen.

Recorded a special income of 1,882 million yen from a grant by the Ministry of Health, Labour and Welfare in the third quarter of the fiscal year ending March 2026.

Entered into an exclusive license agreement with Italfarmaco for the Duchenne Muscular Dystrophy treatment Givinostat in Japan, initiating a strategic partnership in rare disease therapeutics.